HJ-004

HJ-004 is an orally bioavailable, first-in-class pan-EGFR mutation targeted protein degrader (TPD) developed by Jing Medicine Technology (Shanghai) Ltd. It is designed to address resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs) like osimertinib in non-small cell lung cancer (NSCLC). HJ-004 induces the selective degradation of mutant EGFR proteins—including classical, rare, and exon 20 insertion mutations—via E3 ligase-mediated ubiquitination and the proteasomal pathway, while sparing wild-type EGFR. This selectivity provides a significant therapeutic window, potentially avoiding common EGFR-related toxicities such as skin rash and diarrhea. The compound has demonstrated potent antitumor activity in various preclinical models and has received Investigational New Drug (IND) clearance from the U.S. FDA and China NMPA.